EGFR and non-small cell lung carcinoma: Epidermal growth factor receptor(EGFR) mutation is one of the most critical biomarkers in non-small cell lung cancer (NSCLC), holding significant clinical implications for guiding targeted therapy selection and prognostic assessment in patients.